Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
In May 2010, the U.S FDA granted Fast Track designation to CDX-011 for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer.[1]
^"Celldex Therapeutics Announces Initiation Of Randomized Phase 2b Clinical Trial Of CDX-011 In Advanced Breast Cancer". 22 Sep 2010. Archived from the original on 4 November 2010. Retrieved 8 November 2010.
and 8 Related for: Glembatumumab vedotin information
Glembatumumabvedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane...
is the target of the antibody glembatumumab (CR011) which is used in the antibody-drug conjugate glembatumumabvedotin (CDX-011, CR011-vcMMAE) which is...
but predominantly affects cancer cells if used in conjugates like glembatumumabvedotin. A chelator for binding a radioisotope can be attached. Pendetide...
Global Information
(what is this?) (verify)